263 related articles for article (PubMed ID: 7018668)
1. Adoptive therapy of established syngeneic leukemia by cells primarily sensitized in vitro.
Cheever MA; Greenberg PD; Fefer A
Cancer Res; 1981 Jul; 41(7):2658-63. PubMed ID: 7018668
[TBL] [Abstract][Full Text] [Related]
2. Therapy of leukemia by nonimmune syngeneic spleen cells.
Cheever MA; Greenberg PD; Fefer A
J Immunol; 1980 May; 124(5):2137-42. PubMed ID: 7365249
[TBL] [Abstract][Full Text] [Related]
3. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors.
Cheever MA; Greenberg PD; Fefer A
J Immunol; 1980 Aug; 125(2):711-4. PubMed ID: 6156213
[TBL] [Abstract][Full Text] [Related]
4. Immunochemotherapy of transplantable Moloney leukemia with cyclophosphamide and allogeneic spleen lymphocytes and reversal of graft-versus-host disease with alloantiserum.
Kende M; Keys LD; Gaston M; Goldin A
Cancer Res; 1975 Feb; 35(2):346-51. PubMed ID: 234033
[TBL] [Abstract][Full Text] [Related]
5. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
Cohen P; Vourka-Karussis U; Weiss L; Slavin S
J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
[TBL] [Abstract][Full Text] [Related]
7. Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells.
Berenson JR; Einstein AB; Fefer A
J Immunol; 1975 Jul; 115(1):234-8. PubMed ID: 1080165
[TBL] [Abstract][Full Text] [Related]
8. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
Zeis M; Uharek L; Glass B; Gaska T; Gassmann W; Mueller-Ruchholtz W
Bone Marrow Transplant; 1994 Nov; 14(5):711-5. PubMed ID: 7889004
[TBL] [Abstract][Full Text] [Related]
9. Occurrence of tumor antigen pRL1a specific CD8 T cells in spleen cells from syngeneic BALB/c, semiallogeneic (BALB/c x C57BL/6)F1 and allogeneic C57BL/6 mice.
Hata H; Uenaka A; Takada I; Kenjo A; Takahashi M; Ono T; Fujita T; Nakayama E
Int J Oncol; 2002 May; 20(5):1019-25. PubMed ID: 11956599
[TBL] [Abstract][Full Text] [Related]
10. Tumor sponge implantation: an in vivo method for studying syngeneic, primary antitumor lymphocyte responses.
Vallera DA; Mentzer SJ; Maizel SE
Cancer Res; 1982 Feb; 42(2):397-404. PubMed ID: 7055792
[TBL] [Abstract][Full Text] [Related]
11. Suppression of the in vitro secondary response to syngeneic tumor and of in vivo tumor therapy with immune cells by culture-induced suppressor cells.
Greenberg PD; Cheever M; Fefer A
J Immunol; 1979 Aug; 123(2):515-22. PubMed ID: 222839
[TBL] [Abstract][Full Text] [Related]
12. Suppression of secondary cellular immunity to a tumor allograft by cyclophosphamide and 1,3-bis(2-chloroethyl)-1-nitrosourea.
Einstein AB; Fass L; Fefer A
Cancer Res; 1975 Mar; 35(3):492-6. PubMed ID: 1078784
[TBL] [Abstract][Full Text] [Related]
13. Drug-mediated immunogenic changes of virus-induced leukemia in vivo.
Houchens DP; Bonmassar E; Gaston MR; Kende M; Goldin A
Cancer Res; 1976 Apr; 36(4):1347-52. PubMed ID: 1260759
[TBL] [Abstract][Full Text] [Related]
14. Chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro: effect of culture duration on therapeutic efficacy.
Cheever MA; Greenberg PD; Fefer A
J Natl Cancer Inst; 1981 Jul; 67(1):169-73. PubMed ID: 6942187
[TBL] [Abstract][Full Text] [Related]
15. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity.
Shu SY; Chou T; Sakai K
J Immunol; 1989 Jul; 143(2):740-8. PubMed ID: 2738408
[TBL] [Abstract][Full Text] [Related]
16. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
[TBL] [Abstract][Full Text] [Related]
17. Adoptive immunotherapy in tumor-bearing mice with OK-432-induced killer cells.
Ujiie T
Jpn J Exp Med; 1988 Apr; 58(2):109-14. PubMed ID: 3261814
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of tumor cells modified by trinitrobenzene suflonic acid (TNBS).
Kedar E; Unger E; Galili N; Klein G; Asjo B; Bonavida B; Naor D
Prog Clin Biol Res; 1976; 9():109-21. PubMed ID: 1030796
[TBL] [Abstract][Full Text] [Related]
19. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors.
Korbelik M; Dougherty GJ
Cancer Res; 1999 Apr; 59(8):1941-6. PubMed ID: 10213504
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
Ye QW; Mokyr MB
Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
